BIRC2 and plasma cell myeloma: Use of the SMAC-mimetic Birinapant, which has been described to activate alternative NF-κB activity in multiple myeloma cells [62], revealed that this compound is less active than AZD5582 in degrading cIAP1 in the Jurkat T-cell line (see Figure A2A; cIAP1 expression diminished by approximately 40%), and also less effective in selectively inducing processing of p100 into p52 in Jurkat T-cells (Figure A2A).